Andrew Kidd Net Worth

The estimated Net Worth of Andrew Kidd is at least $2.13 million dollars as of 17 May 2021. Mr. Kidd owns over 130,000 units of Aptinyx Inc stock worth over $8,487 and over the last 6 years he sold APTX stock worth over $0. In addition, he makes $2,121,200 as Chief Operating Officer at Aptinyx Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Kidd APTX stock SEC Form 4 insiders trading

Andrew has made over 2 trades of the Aptinyx Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 130,000 units of APTX stock worth $7,930 on 17 May 2021.

The largest trade he's ever made was exercising 130,000 units of Aptinyx Inc stock on 17 May 2021 worth over $7,930. On average, Andrew trades about 15,189 units every 117 days since 2018. As of 17 May 2021 he still owns at least 139,133 units of Aptinyx Inc stock.

You can see the complete history of Mr. Kidd stock trades at the bottom of the page.

Andrew Kidd biography

Andrew Kidd serves as Chief Operating Officer of the Company. He was previously at Baxter International for over ten years, most recently as senior vice president of strategy and business development. Prior to that he held a number of commercial leadership positions including general manager of Baxter Canada, global franchise head for surgical care, and general manager of U.S. anesthesia and cardiovascular. Before joining Baxter he worked at The Boston Consulting Group both in London and then Chicago focused on pharmaceutical and other healthcare clients. Mr. Kidd received a BM BCh medical degree from the University of Oxford and a B.A. in medical sciences from the University of Cambridge.

What is the salary of Andrew Kidd?

As the Chief Operating Officer of Aptinyx Inc, the total compensation of Andrew Kidd at Aptinyx Inc is $2,121,200. There are 2 executives at Aptinyx Inc getting paid more, with Norbert Riedel having the highest compensation of $5,635,420.

How old is Andrew Kidd?

Andrew Kidd is 44, he's been the Chief Operating Officer of Aptinyx Inc since 2019. There are 9 older and no younger executives at Aptinyx Inc. The oldest executive at Aptinyx Inc is Elisha Gould, 63, who is the Independent Director.

What's Andrew Kidd's mailing address?

Andrew's mailing address filed with the SEC is C/O APTINYX INC., 909 DAVIS ST SUITE 600, EVANSTON, IL, 60201.

Insiders trading at Aptinyx Inc

Over the last 6 years, insiders at Aptinyx Inc have traded over $0 worth of Aptinyx Inc stock and bought 10,337,357 units worth $55,328,087 . The most active insiders traders include Street Partners Llc Adams, Patrick G Enright et James N Topper. On average, Aptinyx Inc executives and independent directors trade stock every 35 days with the average trade being worth of $18,161. The most recent stock trade was executed by Joan W. Miller on 13 January 2022, trading 17,700 units of APTX stock currently worth $50,091.

What does Aptinyx Inc do?

welcome to our company page and thank you for your interest in aptinyx inc. aptinyx is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the nmda receptor to enhance pathways involved with nerve cell communication. our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need. at aptinyx, we remain committed and responsive to our employees. we offer an engaging work environment, challenging work assignments, and competitive compensation and benefits. if you are interested in learning more, please visit our website at www.aptinyx.com.

Complete history of Mr. Kidd stock trades at Aptinyx Inc

Aptinyx Inc executives and stock owners

Aptinyx Inc executives and other stock owners filed with the SEC include:

• Norbert Riedel,
  President, Chief Executive Officer, Director
• Ashish Khanna,
  Chief Financial Officer, Chief Business Officer
• Andrew Kidd,
  Chief Operating Officer
• Dr. Norbert G. Riedel,
  Exec. Chairman
• Dr. Andrew D. Kidd B.M. B.Ch., M.D.,
  CEO, Pres & Director
• Ashish Khanna,
  CFO & Chief Bus. Officer
• Henry Gosebruch,
  Independent Director
• Rachel Sherman,
  Independent Director
• Robert Hombach,
  Independent Director
• Patrick Enright,
  Independent Chairman of the Board
• Adam Koppel,
  Independent Director
• Elisha Gould,
  Independent Director
• Tim Noffke,
  VP of Program Management & Chief of Staff
• Dr. Harald Murck M.D., Ph.D.,
  VP of Clinical & Medical Affairs
• Patrick Flavin,
  Sr. Mang. of Corp. Devel. & Investor Relations
• Dr. Kathryn King Ph.D.,
  Sr. VP of Clinical & CMC Operations
• Molly Dir,
  VP of HR
• Juan Estupinan,
  VP of Fin. & Accounting and Controller
• Capital Life Sciences Inves...,
  
• Gilmore Neil O'neill,
  
• Terry P Gould,
  
• Leaf Venture Management Iii...,
  
• David Houck,
  Chief Development Officer
• Torsten M. Madsen,
  Chief Medical Officer
• James N Topper,
  Director
• Life Sciences Viii, L.P.Fhm...,
  
• Capital Partners Ii, Llc Ta...,
  
• Wilbur H Gantz,
  Director
• Joseph R. Moskal,
  Chief Scientific Officer
• Street Partners Llc Adams,
  10% owner
• Liam Ratcliffe,
  Director
• Joan W. Miller,